mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids

American Journal of Respiratory Cell and Molecular Biology

Volumn 39, Issue 5, 2008, Pages 576-583

  Wilson, Shannon M ^a   Barbone, Dario ^a,c   Yang, Tsung Ming ^a,c   Jablons, David M ^b,c   Bueno, Raphael ^d   Sugarbaker, David J ^d   Nishimura, Stephen L ^b,c   Gordon, Gavin J ^d   Broaddus, V Courtney ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Apoptosis; Biomarker; Ex vivo; S6K; TRAIL

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; SMALL INTERFERING RNA; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; CYCLOHEXIMIDE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; MORPHOLINE DERIVATIVE; PROTEIN KINASE; S6 KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; MESOTHELIOMA; MESOTHELIUM CELL; PROTEIN EXPRESSION; SPHEROID CELL; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; MULTIDRUG RESISTANCE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; CYCLOHEXIMIDE; DEOXYCYTIDINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MESOTHELIOMA; MORPHOLINES; PHOSPHORYLATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; SPHEROIDS, CELLULAR; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 55249102222     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2007-0460OC     Document Type: Article

References (39)

1. Wendel HG, Lowe SW. Reversing drug resistance in vivo. Cell Cycle 2004;3:847-849.
2. Smalley KSM, Lioni M, Herlyn M. Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol 2006;42:242-247.
3. Pampaloni F, Reynoud EG, Stelzer EHK. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007;8:839-845.
4. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004;9:273-285.
5. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
6. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007;13:433-442.
7. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-337.
8. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Z, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601.
9. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508.
10. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109-3114.
11. Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol 2007;4:344-352.
12. Liu W, Bodle E, Chen JY, Gao M, Rosen GD, Broaddus VC. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol 2001;25:111-118.
13. Vivo C, Liu W, Broaddus VC. JNK contributes to apoptotic synergy induced by TRAIL plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem 2003;278:25461-25467.
14. Abayasiriwardana KS, Barbone D, Kim KU, Vivo C, Lee KK, Dansen TB, Hunt AE, Evan GI, Broaddus VC. Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low dose anisomycin via Bim. Mol Cancer Ther 2007; (In press).
15. Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z, Jablons DM, Nishimura SL, Broaddus VC. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 2005;33:541-548.
16. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB, Testa JR. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005;24:6080-6089.
17. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006;125:733-747.
18. Kim BK. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 2005;15:365-377.
19. Wang X, Beugnet A, Murakami M, Yamanaka S, Proud CG. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol 2005;25:2558-2572.
20. Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC. mTOR contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 2008;283:13021-13030.
21. Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2007;32:676-681.
22. Abbuzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Watterlee W, Raber MN. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-498.
23. Desoize B, Jardillier JC. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 2000;36:193-207.
24. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-7464.
25. Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, Oshima RG, Abraham RT. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res 2005;65:5325-5336.
26. Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K, Abraham RT. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 2007;6:2505-2514.
27. Delahaye M, de John AA, Versnel MA, Hoogsteden HC, Teeling P, van der Kwast TH. Cytopathology of malignant mesothelioma: reappraisal of the diagnostic value of collagen cores. Cytopathology 1990;1:137-145.
28. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001;98:9666-9670.
29. Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPs translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005;25:8809-8823.
30. Edinger AL, Thompson CB. An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival. Oncogene 2004;23:5654-5663.
31. Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006;3:448-457.
32. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settlemen J. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006;10:425-435.
33. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484.
34. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by ERK: implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179-193.
35. Reiling JH, Sabatini DM. Stress and mTORture signaling. Oncogene 2006;25:6373-6383.
36. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L,O'Toole T, Gibbons JJ, Belldegrun AS, Figlin RA. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer 2007;109:2257-2267.
37. Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R, Filipits M. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 2007;13:4795-4799.
38. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy. Cell Cycle 2006;5:1779-1787.
39. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-592.